
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032
Description
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Report and Forecast 2024-2032
The global epidermal growth factor receptor (EGFR) inhibitors market size was valued at USD 9.2 billion in 2023. It is expected to grow at a CAGR of 10.50% during the forecast period of 2024-2032, driven by rising trend towards combining EGFR inhibitors with other therapeutic modalities. The market is experiencing robust growth and is expected to reach USD 22.5 billion by 2032.
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
The global epidermal growth factor receptor (EGFR) inhibitors market is experiencing substantial growth due to the increasing prevalence of cancer and the rising demand for targeted cancer therapies. EGFR inhibitors are a class of drugs designed to block the activity of the EGFR, a protein that plays a crucial role in the growth and spread of cancer cells. These inhibitors are used primarily in the treatment of non-small cell lung cancer (NSCLC), colorectal cancer, and other epithelial cancers.
Market Drivers
- Rising Cancer Incidence: The increasing global incidence of various cancers, particularly lung and colorectal cancers, is a significant driver of the EGFR inhibitors market. The need for effective and targeted treatments is propelling the demand for EGFR inhibitors.
- Advancements in Biotechnology: Continuous advancements in biotechnology and pharmaceutical research are leading to the development of more effective and less toxic EGFR inhibitors. Innovations in drug formulations and delivery methods are enhancing patient outcomes and expanding market opportunities.
- Growing Awareness and Screening Programs: Enhanced awareness about cancer and the importance of early detection through screening programs are contributing to the early diagnosis of cancers. This, in turn, increases the adoption of EGFR inhibitors as part of early intervention strategies.
- Favorable Regulatory Environment: Regulatory bodies such as the FDA and EMA have been approving a growing number of EGFR inhibitors for various cancer indications. Accelerated approval processes and orphan drug designations are facilitating faster market entry for new treatments.
- High Treatment Costs: The high cost of EGFR inhibitors poses a significant challenge, limiting their accessibility, especially in developing regions. The financial burden on healthcare systems and patients can impede market growth.
- Resistance to EGFR Inhibitors: The development of resistance to EGFR inhibitors over time is a critical challenge. Cancer cells can develop mutations that render the inhibitors less effective, necessitating the development of second and third-generation inhibitors.
- Side Effects and Toxicity: Despite their targeted action, EGFR inhibitors can cause side effects such as skin rash, diarrhea, and interstitial lung disease. Managing these adverse effects is crucial to maintaining patient compliance and treatment efficacy.
- Competition from Other Therapies: The market faces competition from other targeted therapies and immunotherapies, such as checkpoint inhibitors and monoclonal antibodies, which can impact the adoption of EGFR inhibitors.
- Development of Next-Generation Inhibitors: The ongoing research and development of next-generation EGFR inhibitors that can overcome resistance and have improved safety profiles offer significant growth opportunities. These novel inhibitors are expected to enhance treatment efficacy and patient outcomes.
- Expansion into Emerging Markets: Expanding the availability and accessibility of EGFR inhibitors in emerging markets presents a substantial growth opportunity. Increased healthcare expenditure, improving healthcare infrastructure, and rising awareness in these regions can drive market expansion.
- Combination Therapies: Exploring combination therapies involving EGFR inhibitors and other treatment modalities, such as chemotherapy, immunotherapy, and radiation, can enhance therapeutic outcomes. Combination approaches can potentially overcome resistance and improve overall survival rates.
- Personalized Medicine: The trend towards personalized medicine, where treatments are tailored based on individual genetic profiles, is likely to boost the demand for EGFR inhibitors. Advances in genetic testing and biomarker identification will enable more precise and effective use of these inhibitors.
- Partnerships and Collaborations: Strategic partnerships and collaborations between pharmaceutical companies, research institutions, and healthcare providers can accelerate the development and commercialization of new EGFR inhibitors. Collaborative efforts can also facilitate large-scale clinical trials and regulatory approvals.
Here are some market trends in the global epidermal growth factor receptor (EGFR) inhibitors market:
- Increasing Focus on Precision Medicine
- Development of Combination Therapies
- Advancements in Next-Generation EGFR Inhibitors
- Expansion in Emerging Markets
- Growing Use of Liquid Biopsies
- Strategic Collaborations and Partnerships
- Regulatory Approvals and Orphan Drug Designations
- Patient Assistance Programs
- Rising Investment in Oncology Research
- Enhanced Patient Education and Awareness
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Segmentation
Market Breakup by Application
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
Market Breakup by Route of Administration
- Oral
- Injectables
- Others
Market Breakup by Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Competitive Landscape
The EGFR inhibitors market features key players such as Amgen Inc., AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., Johnson & Johnson Services, Inc., Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Astellas Pharma Inc., Merck KGaA, and Daiichi Sankyo Company. Common market activities include mergers and acquisitions to expand product portfolios and market reach, extensive research initiatives aimed at developing next-generation inhibitors and combination therapies, and frequent product introductions to offer innovative treatments. Partnerships and collaborations are also prevalent, enhancing research capabilities and accelerating the commercialization of new therapies, thereby driving market growth.
Key Questions Answered in the Report
- What is the current and future performance of the epidermal growth factor receptor (EGFR) inhibitors market?
- What are the main challenges facing the epidermal growth factor receptor (EGFR) inhibitors market?
- What are the key drivers of the epidermal growth factor receptor (EGFR) inhibitors market?
- What emerging trends are shaping the future of the epidermal growth factor receptor (EGFR) inhibitors market?
- How is liquid biopsy technology enhancing the management of patients on EGFR inhibitors?
- How do strategic collaborations among pharmaceutical companies impact the development of EGFR inhibitors?
- Why is lung cancer the largest segment in the EGFR inhibitors market?
- Why are injectables significant in the EGFR inhibitors market?
- Why do hospital pharmacies lead the EGFR inhibitors market?
- What are the common strategies used by key players in the epidermal growth factor receptor (EGFR) inhibitors market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global epidermal growth factor receptor (EGFR) inhibitors market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the epidermal growth factor receptor (EGFR) inhibitors market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the epidermal growth factor receptor (EGFR) inhibitors industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
200 Pages
- 1 Preface
- 2 Report Coverage – Key Segmentation and Scope
- 3 Report Description
- 3.1 Market Definition and Outlook
- 3.2 Properties and Applications
- 3.3 Market Analysis
- 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
- 5.1 Overview
- 5.2 Key Drivers
- 5.3 Key Developments
- 5.4 Competitive Structure
- 5.5 Key Industrial Trends
- 6 Market Snapshot
- 6.1 Global
- 6.2 Regional
- 7 Opportunities and Challenges in the Market
- 8 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 8.1 Key Industry Highlights
- 8.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market (2018-2023)
- 8.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast (2024-2032)
- 8.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by Indication
- 8.4.1 Lung Cancer
- 8.4.1.1 Historical Trend (2018-2023)
- 8.4.1.2 Forecast Trend (2024-2032)
- 8.4.2 Colorectal Cancer
- 8.4.2.1 Historical Trend (2018-2023)
- 8.4.2.2 Forecast Trend (2024-2032)
- 8.4.3 Breast Cancer
- 8.4.3.1 Historical Trend (2018-2023)
- 8.4.3.2 Forecast Trend (2024-2032)
- 8.4.4 Others
- 8.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by Region
- 8.5.1 North America
- 8.5.1.1 Historical Trend (2018-2023)
- 8.5.1.2 Forecast Trend (2024-2032)
- 8.5.2 Europe
- 8.5.2.1 Historical Trend (2018-2023)
- 8.5.2.2 Forecast Trend (2024-2032)
- 8.5.3 Asia Pacific
- 8.5.3.1 Historical Trend (2018-2023)
- 8.5.3.2 Forecast Trend (2024-2032)
- 8.5.4 Latin America
- 8.5.4.1 Historical Trend (2018-2023)
- 8.5.4.2 Forecast Trend (2024-2032)
- 8.5.5 Middle East and Africa
- 8.5.5.1 Historical Trend (2018-2023)
- 8.5.5.2 Forecast Trend (2024-2032)
- 9 North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 9.1 United States of America
- 9.1.1 Historical Trend (2018-2023)
- 9.1.2 Forecast Trend (2024-2032)
- 9.2 Canada
- 9.2.1 Historical Trend (2018-2023)
- 9.2.2 Forecast Trend (2024-2032)
- 10 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 10.1 United Kingdom
- 10.1.1 Historical Trend (2018-2023)
- 10.1.2 Forecast Trend (2024-2032)
- 10.2 Germany
- 10.2.1 Historical Trend (2018-2023)
- 10.2.2 Forecast Trend (2024-2032)
- 10.3 France
- 10.3.1 Historical Trend (2018-2023)
- 10.3.2 Forecast Trend (2024-2032)
- 10.4 Italy
- 10.4.1 Historical Trend (2018-2023)
- 10.4.2 Forecast Trend (2024-2032)
- 10.5 Others
- 11 Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 11.1 China
- 11.1.1 Historical Trend (2018-2023)
- 11.1.2 Forecast Trend (2024-2032)
- 11.2 Japan
- 11.2.1 Historical Trend (2018-2023)
- 11.2.2 Forecast Trend (2024-2032)
- 11.3 India
- 11.3.1 Historical Trend (2018-2023)
- 11.3.2 Forecast Trend (2024-2032)
- 11.4 ASEAN
- 11.4.1 Historical Trend (2018-2023)
- 11.4.2 Forecast Trend (2024-2032)
- 11.5 Australia
- 11.5.1 Historical Trend (2018-2023)
- 11.5.2 Forecast Trend (2024-2032)
- 11.6 Others
- 12 Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 12.1 Brazil
- 12.1.1 Historical Trend (2018-2023)
- 12.1.2 Forecast Trend (2024-2032)
- 12.2 Argentina
- 12.2.1 Historical Trend (2018-2023)
- 12.2.2 Forecast Trend (2024-2032)
- 12.3 Mexico
- 12.3.1 Historical Trend (2018-2023)
- 12.3.2 Forecast Trend (2024-2032)
- 12.4 Others
- 13 Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Analysis
- 13.1 Saudi Arabia
- 13.1.1 Historical Trend (2018-2023)
- 13.1.2 Forecast Trend (2024-2032)
- 13.2 United Arab Emirates
- 13.2.1 Historical Trend (2018-2023)
- 13.2.2 Forecast Trend (2024-2032)
- 13.3 Nigeria
- 13.3.1 Historical Trend (2018-2023)
- 13.3.2 Forecast Trend (2024-2032)
- 13.4 South Africa
- 13.4.1 Historical Trend (2018-2023)
- 13.4.2 Forecast Trend (2024-2032)
- 13.5 Others
- 14 Market Dynamics
- 14.1 SWOT Analysis
- 14.1.1 Strengths
- 14.1.2 Weaknesses
- 14.1.3 Opportunities
- 14.1.4 Threats
- 14.2 Porter’s Five Forces Analysis
- 14.2.1 Supplier’s Power
- 14.2.2 Buyer’s Power
- 14.2.3 Threat of New Entrants
- 14.2.4 Degree of Rivalry
- 14.2.5 Threat of Substitutes
- 14.3 Key Indicators for Demand
- 14.4 Key Indicators for Price
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Company Profiles
- 15.2.1 Amgen Inc.
- 15.2.1.1 Company Overview
- 15.2.1.2 Product Portfolio
- 15.2.1.3 Demographic Reach and Achievements
- 15.2.1.4 Certifications
- 15.2.2 Novartis AG
- 15.2.2.1 Company Overview
- 15.2.2.2 Product Portfolio
- 15.2.2.3 Demographic Reach and Achievements
- 15.2.2.4 Certifications
- 15.2.3 AstraZeneca PLC
- 15.2.3.1 Company Overview
- 15.2.3.2 Product Portfolio
- 15.2.3.3 Demographic Reach and Achievements
- 15.2.3.4 Certifications
- 15.2.4 Eli Lilly and Company
- 15.2.4.1 Company Overview
- 15.2.4.2 Product Portfolio
- 15.2.4.3 Demographic Reach and Achievements
- 15.2.4.4 Certifications
- 15.2.5 F. Hoffmann-La Roche Ltd.
- 15.2.5.1 Company Overview
- 15.2.5.2 Product Portfolio
- 15.2.5.3 Demographic Reach and Achievements
- 15.2.5.4 Certifications
- 15.2.6 Johnson & Johnson Services, Inc.
- 15.2.6.1 Company Overview
- 15.2.6.2 Product Portfolio
- 15.2.6.3 Demographic Reach and Achievements
- 15.2.6.4 Certifications
- 15.2.7 Others
- 16 Key Trends and Developments in the Market
- List of Key Figures and Tables
- 1. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market: Key Industry Highlights, 2018 and 2032
- 2. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Indication (USD Million), 2018-2023
- 3. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Indication (USD Million), 2024-2032
- 4. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Region (USD Million), 2018-2023
- 5. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Region (USD Million), 2024-2032
- 6. North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
- 7. North America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
- 8. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
- 9. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
- 10. Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
- 11. Asia Pacific Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
- 12. Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
- 13. Latin America Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
- 14. Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Historical Market: Breakup by Country (USD Million), 2018-2023
- 15. Middle East and Africa Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Forecast: Breakup by Country (USD Million), 2024-2032
- 16. Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Structure
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.